Real time COVID-19 epidemiology registry monitoring population infection progress using digital therapeutics platform for remote patient monitoring and integrated chronic disease management with mobile app, Artificial Intelligence bots, IoT wearable devices and intelligent cloud computing algorithms.
Users self-report symptoms, mental health assessment, chronic illness status and vital sign measures on a daily basis for risk assessment and preventive treatment with a variety of digital tools using mobile app, access interactive chat-bots and Coromec real time epidemiology website.
Coromec registry is a real time epidemiology solution for pandemic public health stakeholders to enable immediate reporting, assess population risk prediction for avoiding hospitalization in a pandemic. Coromec is a IRB approved research study that anyone (healthy or not) at least 18 years of age can enroll at www.coromec.org.
Clinical Trial: NCT04678193clinicaltrials.gov
Keeping Health and Privacy in Mind
Data collection is electronically de-identified and secured remotely, preventing infection spread.
SARS-CoV-2 is a beta coronavirus similar to SARS and Middle East respiratory syndrome (MERS), the coronaviruses responsible for the last two epidemics in 2003 and 2012, respectively. Currently, more than 65 million infections have been reported worldwide and more than 1.5 Million have died due to COVID-19 in a fast moving pandemic <Map Below>. The United States has reported the highest number of cases and deaths in the world. As the pandemic has overwhelmed healthcare systems, better therapies are desperately needed to prevent positive cases who are asymptomatic or mildly symptomatic from worsening clinical status leading to hospitalization.
Individuals diagnosed with COVID-19 can manifest a litany of symptoms including fever, dry cough, dyspnea, myalgia, and fatigue. Within a few days of symptom onset, some patients rapidly progress to respiratory failure requiring mechanical ventilation. Elderly patients and those with medical comorbidities such as diabetes, hypertension, obesity, underlying cardio-pulmonary disease, immunocompromised state, kidney disease, and cancer are at greater risk of developing worsening comorbidities rapidly progressing to Acute Respiratory Distress Syndrome and multi-organ failure, requiring hospitalization and prolonged care in the ICU. These patients also have a higher mortality rate compared to younger patients without comorbid conditions. A standardized approach to risk screening, testing, preventing hospitalizations and treating patients with COVID-19 continues to be a global challenge lacking peer reviewed clinical validation.
Project Coromec aim is a real time COVID-19 epidemiology registry to assess the feasibility of monitoring subject infection progress using Vitalbeat digital therapeutics monitoring platform for remote patient monitoring and integrated chronic disease management with mobile app, AI-bots, IoT Wearables and cloud computing algorithms developed by digital therapeutics company Aventyn, Inc., in collaboration with Intel Corp., clinicians and scientists from Abrazo Health, Karolinska Institute, ASU College of Health Solutions with global collaborators. Coromec registry is a real time epidemiology solution deploying Vitalbeat health application platform for pandemic public health stakeholders to enable immediate reporting, assess subject risk prediction for COVID-19 avoiding hospitalization. Healthcare is becoming more intelligent, distributed, and personalized. Intel technologies are helping to enable new era of smart, connected, value-based patient care, remote medicine and monitoring, individually tailored treatment plans, and more-efficient clinical operations. The digital health technology aims to assess predictors of risk and predictors of preventing COVID-19, assess what preventive strategies are being used and the efficacy of treatment strategies for avoiding hospitalization.
A validated approach would enable vulnerable subjects and communities access to pandemic care. Registry data can assist public health scientists in further studies and enable global registries in future pandemic emergencies to help better understand use of digital tools, intelligent algorithms and predict risk outcomes with targeted novel treatment strategies. Coromec is committed to accelerating access to technology that can combat the current pandemic and enable scientific discovery that better prepares our world for future crises.
Coromec enables COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy